I. Zolotukhin

发表

Improved method of recombinant AAV2 delivery for systemic targeted gene therapy.

Jon Dobson, Sihong Song, Terence R Flotte, 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo.

Brendan H. Lee, G. Rogers, R. Herzog, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

TLR9-dependent innate immune responses in the liver The genome of self-complementary AAV vectors increases

Brendan H. Lee, R. Herzog, I. Zolotukhin, 2012 .

The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.

H. Ertl, Brendan H. Lee, R. Herzog, 2011, Blood.

Improved Adeno-associated Viral Gene Transfer to Murine Glioma.

R. Herzog, K. Warrington, I. Zolotukhin, 2013, Journal of genetic syndromes & gene therapy.

A new method for recombinant adeno-associated virus vector delivery to murine diaphragm.

B. Byrne, C. Mah, T. J. Fraites, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Evaluation of primitive murine hematopoietic stem and progenitor cell transduction in vitro and in vivo by recombinant adeno-associated virus vector serotypes 1 through 5.

L. Zhong, Baozheng Li, A. Srivastava, 2006, Human gene therapy.

Potential for cellular stress response to hepatic factor VIII expression from AAV vector

R. Herzog, I. Zolotukhin, D. Markusic, 2016, Molecular therapy. Methods & clinical development.

Engineering and In Vitro Selection of a Novel AAV3B Variant with High Hepatocyte Tropism and Reduced Seroreactivity

S. Zolotukhin, G. González-Aseguinolaza, R. Herzog, 2020, Molecular therapy. Methods & clinical development.

Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models

S. Zolotukhin, R. Herzog, A. Srivastava, 2017, Journal of Translational Medicine.

Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid.

C. Rice, Arun Srivastava, H. Ertl, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Prevalence of neutralizing antibodies against liver-tropic adeno-associated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutions.

C. Ling, Arun Srivastava, A. Srivastava, 2015, Journal of integrative medicine.

Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells.

Xiaomei Wang, L. Morel, R. Herzog, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

High Efficiency Ex Vivo Gene Transfer to Primary Murine B Cells Using Plasmid or Viral Vectors.

B. Sack, R. Herzog, I. Zolotukhin, 2011, Journal of genetic syndromes & gene therapy.

In vitro replication of adeno-associated virus DNA

N. Muzyczka, I. Zolotukhin, X. Zhou, 1994, Journal of virology.

Dual vectors expressing murine factor VIII result in sustained correction of hemophilia A mice.

B. Byrne, H. Kazazian, R. Sarkar, 2003, Human gene therapy.

Type I IFN Sensing by cDCs and CD4+ T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8+ T Cells.

M. Wallet, L. Morel, R. Herzog, 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease

B. Byrne, T. J. Fraites, I. Zolotukhin, 2004, Development.

Biochemical Characterization of Adeno-Associated Virus Rep68 DNA Helicase and ATPase Activities

N. Muzyczka, Xiaohuai Zhou, I. Zolotukhin, 1999, Journal of Virology.

Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells.

M. Wallet, G. Rogers, R. Herzog, 2017, Blood.

Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer

H. Ertl, Brendan H. Lee, L. Morel, 2015, Journal of Innate Immunity.

Cellular Proteins Required for Adeno-Associated Virus DNA Replication in the Absence of Adenovirus Coinfection

B. Stillman, N. Muzyczka, S. Waga, 1998, Journal of Virology.

Identification of linear DNA sequences that specifically bind the adeno-associated virus Rep protein

J. Ryan, N. Muzyczka, Xiaohuai Zhou, 1994, Journal of virology.

Immune Tolerance Induction to Factor IX Through B Cell Gene Transfer – Delineating Between Tolerogenic and Immunogenic B Cells.

Xiaomei Wang, R. Herzog, I. Zolotukhin, 2012 .

Identification of adeno-associated viral vectors suitable for intestinal gene delivery and modulation of experimental colitis.

T. Conlon, C. Mah, I. Zolotukhin, 2012, American journal of physiology. Gastrointestinal and liver physiology.

High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines.

S. Zolotukhin, G. Jayandharan, L. Zhong, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy

T. Kaisho, R. Herzog, W. Xiao, 2021, Frontiers in Immunology.

Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors.

W. Hauswirth, B. Byrne, N. Muzyczka, 2002, Methods.

Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo

T. Conlon, B. Byrne, C. Mah, 2006, Circulation research.

Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B

H. Ertl, G. Rogers, R. Herzog, 2014, Journal of Translational Medicine.

Type I Interferon Sensing by Conventional Dendritic Cells and CD4+ T Help are both Requisite for Cross-priming of AAV Capsid-specific CD8+ T Cells

M. Wallet, L. Morel, I. Zolotukhin, 2019 .

Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses

N. Muzyczka, L. Govindasamy, M. Agbandje-McKenna, 2008, Proceedings of the National Academy of Sciences.

AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells.

P. Stacpoole, A. Srivastava, I. Zolotukhin, 2009, Molecular genetics and metabolism.

Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.

B. Byrne, S. Powers, N. Raben, 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

Dynamics of antigen presentation to transgene product-specific CD4+ T cells and of Treg induction upon hepatic AAV gene transfer

A. Davidoff, R. Herzog, I. Zolotukhin, 2016, Molecular therapy. Methods & clinical development.

Biodistribution of Adeno-Associated Virus Type 2 with Mutations in the Capsid that Contribute to Heparan Sulfate Proteoglycan Binding.

N. Muzyczka, K. Warrington, I. Zolotukhin, 2019, Virus research.

Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield

B. Byrne, R. Samulski, N. Muzyczka, 1999, Gene Therapy.

High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap

B. Byrne, G. Hayward, N. Muzyczka, 1999, Gene Therapy.

Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models

S. Zolotukhin, R. Herzog, T. Nichols, 2017, Journal of Translational Medicine.

The lipofuscin fluorophore A 2 E perturbs cholesterol metabolism in retinal pigment epithelial cells

L. Govindasamy, A. Gleiberman, S. Zolotukhin, 2008 .

Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo

T. Conlon, B. Byrne, C. Mah, 2006, Circulation research.

Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors

B. Byrne, C. Mah, T. J. Fraites, 2005, Gene Therapy.